New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
09:29 EDTRIGL, ABTRigel Pharmaceuticals price target lowered to $8 from $15 at Roth Capital
Roth Capital lowered its target on Rigel after the company's rheumatoid arthritis treatment fostamatinib did not demonstrate equivalence versus Abbott's (ABT) Humira in a Phase II test. The firm reduced its estimates for fostamatinib but maintains a Buy rating on the stock based on valuation.
News For RIGL;ABT From The Last 14 Days
Check below for free stories on RIGL;ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
09:00 EDTABTAbbott and Defense Department to develop portable blood tests
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use